logo
‘Another mind-blowing change': New data suggests mysterious dark energy is evolving

‘Another mind-blowing change': New data suggests mysterious dark energy is evolving

CNN02-04-2025
Summary
New data from a massive cosmic survey suggests mysterious dark energy may be evolving and weakening over time.
The Dark Energy Spectroscopic Instrument has measured light from nearly 15 million galaxies and quasars.
Scientists previously thought dark energy was constant, but findings indicate it behaves in unexpected ways.
If dark energy continues weakening, the universe's expansion could eventually stop or even collapse.
While evidence isn't conclusive, researchers say these findings could fundamentally change our understanding of physics. New hints from one of the most extensive surveys of the cosmos to date suggest that mysterious dark energy may be evolving in ways that could shift how astronomers understand the universe.
Dark energy is a term scientists use to describe an energy or force that accelerates the expansion of the universe. But — although it represents 70% of the energy in the cosmos — researchers still have no idea exactly what dark energy is, said Mustapha Ishak-Boushaki, professor of physics and astrophysics at the University of Texas at Dallas.
Ishak-Boushaki is a cochair of a working group for the Dark Energy Spectroscopic Instrument collaboration, known as DESI. The instrument, now in its fourth year of surveying the sky, can observe light from 5,000 galaxies at the same time. When the project concludes next year, it will have measured the light of about 50 million galaxies.
The collaboration, which includes more than 900 researchers, shared the latest data release from DESI's first three years of observations on March 19. Among its findings are the measurements of nearly 15 million galaxies and quasars, some of the brightest objects in the universe. Ishak-Boushak helped lead the analysis of the latest DESI data release, which suggests that dark energy — long called a 'cosmological constant' given that astronomers thought it was unchanging — is behaving in unexpected ways and may even be weakening over time.
'The discovery of dark energy, nearly 30 years ago, was already the biggest surprise of my scientific lifetime,' said David Weinberg, a professor of astronomy at The Ohio State University who contributed to the DESI analysis, in a statement. 'These new measurements offer the strongest evidence so far that dark energy evolves, which would be another mind-blowing change to our understanding of how the universe works.'
The findings bring astronomers another step closer to unmasking the mysterious nature of dark energy, which may mean that the standard model of how the universe works could also require an update, scientists say.
The Dark Energy Spectroscopic Instrument is atop the National Science Foundation's Nicholas U. Mayall 4-meter Telescope at Kitt Peak National Observatory in Tucson, Arizona. The instrument's 5,000 fiber-optic 'eyes' and extensive surveying capabilities are enabling scientists to build one of the largest 3D maps of the universe and track how dark energy has influenced and shaped the cosmos over the past 11 billion years.
It takes time for the light from celestial objects like galaxies to travel to Earth, which means that DESI can effectively see what the cosmos was like at different points in time, from billions of years ago to the present.
'DESI is unlike any other machine in terms of its ability to observe independent objects simultaneously,' said John Moustakas, a professor of physics at Siena College and colead of the data release.
The newest findings include data on more than double the cosmic objects that were surveyed and presented less than a year ago. Those 2024 revelations first hinted at how dark energy may be evolving.
'We're in the business of letting the universe tell us how it works, and maybe the universe is telling us it's more complicated than we thought it was,' said Andrei Cuceu, a postdoctoral researcher at the US Department of Energy's Lawrence Berkeley National Laboratory, which manages DESI, and cochair of DESI's Lyman-alpha working group, in a statement. 'It's interesting and gives us more confidence to see that many different lines of evidence are pointing in the same direction.'
DESI can measure what scientists call the baryon acoustic oscillation, or BAO, scale — essentially how events that occurred early in the universe left behind patterns in how matter is distributed across the cosmos. Astronomers look to the BAO scale, with separations of matter by about 480 million light-years, as a standard ruler.
'This separation scale is like a really gigantic ruler in space that we can use to measure distances, and we use the combination of these distance and redshifts (speed objects are moving away from us) to measure the expansion of the universe,' said Paul Martini, a coordinator of the analysis and professor of astronomy at The Ohio State University.
Measuring dark energy's influence across the history of the universe shows how dominant a force it has been.
Researchers began to notice when they combined these observations with other measurements of light across the universe such as exploding stars, the gravity-warped light of distant galaxies, and the light leftover from the dawn of the universe, called the cosmic microwave background, the DESI data shows that dark energy's impact could be weakening over time.
'If this continues then eventually dark energy will not be the dominant force in the universe,' Ishak-Boushak said in an email. 'Therefore the universe expansion will stop accelerating and will go at a constant rate or even in some models could also stop and collapse back. Of course, these futures are very remote and will take billions and billions of years to happen. I've worked on the question of cosmic acceleration for 25 years, and my perspective is, if the evidence continues to grow, and it is likely to, then this will be huge for cosmology and all of physics.'
There isn't enough evidence yet to declare a groundbreaking discovery that definitively says dark energy is evolving and weakening, but that could change within just a couple of years, Ishak-Boushak said.
'My first big question is if we will continue to see evidence for evolving dark energy as our measurements get better and better,' Martini said. 'If we do get to the point where the evidence is overwhelming, then my next questions will be: How does dark energy evolve? And what are the most likely physical explanations?'
The new data release could also help astrophysicists better understand how galaxies and black holes evolve and the nature of dark matter. Although dark matter has never been detected, it is believed to make up 85% of the total matter in the universe.
Scientists involved with the collaboration are eager to improve their measurements using DESI.
'Whatever the nature of dark energy is, it will shape the future of our universe,' said Michael Levi, DESI director and a scientist at the Lawrence Berkeley National Laboratory. 'It's pretty remarkable that we can look up at the sky with our telescopes and try to answer one of the biggest questions that humanity has ever asked.'
A new experiment called Spec-S5, or Stage 5 Spectroscopic Experiment, could measure more than 10 times as many galaxies as DESI to study both dark energy and dark matter, Martini said.
'Spec-S5 would use telescopes in both the northern and southern hemispheres to map galaxies across the entire sky,' Martini said. 'We are also excited about how the (Vera) Rubin telescope will study supernovae, and provide a new, uniform dataset to study the (universe's) expansion history.'
Other space observatories, like the Euclid space telescope and the Nancy Grace Roman Space Telescope, set to launch in 2027, will also contribute more key measurements of dark matter and dark energy in the coming years that could help fill in the gaps, said Jason Rhodes, an observational cosmologist at NASA's Jet Propulsion Laboratory in Pasadena, California. Rhodes, who is not involved in DESI, is the US science lead for Euclid and principal investigator for NASA's Euclid dark energy science team.
Rhodes, who calls the results intriguing, said the data shows a slight but persistent tension between measurements from the early days of the universe and those from the later universe.
'(This means) that our simplest model of dark energy doesn't quite allow for the early universe we observe to evolve into the late universe we observe,' Rhodes said. 'DESI results (and some other recent results) seem to indicate that a more complex model of dark energy is preferred. This is truly exciting because it may mean that new, unknown, physics governs the evolution of the universe. DESI has given us tantalizing results that may indicate a new model of cosmology is needed.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

Associated Press

time3 days ago

  • Associated Press

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855

Photos: Inside the Allen Institute for AI's new HQ in Seattle's first mass-timber office building
Photos: Inside the Allen Institute for AI's new HQ in Seattle's first mass-timber office building

Geek Wire

time5 days ago

  • Geek Wire

Photos: Inside the Allen Institute for AI's new HQ in Seattle's first mass-timber office building

The view from one of Ai2's outdoor patios, overlooking Lake Union and the Seattle skyline. (Photos by Todd Bishop, GeekWire) It was a big news week for Seattle's Allen Institute for Artificial Intelligence (Ai2), including the announcement of a new AI robotics initiative and a landmark grant from Nvidia and the National Science Foundation to lead the creation of the future AI backbone for U.S. scientific research. But the nonprofit research institute also reached another milestone in recent weeks: moving into its new 50,000-square-foot headquarters in Seattle's first large-scale mass-timber commercial building. A lobby seating area at Ai2's new headquarters in Northlake Commons. (GeekWire Photo / Todd Bishop) The new Ai2 space, in the Northlake Commons project on the north shore of Lake Union, is now the central gathering and workspace for the organization and its team of about 225 people. Ai2 occupies one floor of the five-story building. It's a short drive up the road from Ai2's prior headquarters, and within walking or biking distance of the University of Washington, where many of Ai2's researchers are also affiliated with the UW Allen School of Computer Science & Engineering. Mass timber is an engineered wood product made by binding layers of wood together into strong, large structural panels and beams, providing the strength of steel or concrete with a lower carbon footprint. The mass-timber elements are visible throughout the space and common areas of the building. An outdoor meeting area at the Northlake Commons building. The space includes large meeting rooms, private call rooms, a podcast and video studio, large doors that open up to outside patios on warm days, and a dining area and gathering space with sweeping views of Lake Union and downtown. The interior design deliberately avoids a traditional 'sea of desks' layout in favor of smaller groupings of workstations where researchers can collaborate while remaining connected through walkways and sight lines. There's even enough space for a simulated home environment in the Ai2 robotics lab, including two kitchens, allowing researchers to test their latest AI robotics technology in conditions that mimic a real-world household. The Ai2 logo in the lobby of the new headquarters. Northlake Commons was designed by Seattle-based architect Weber Thompson and built by general contractor Swinerton. News of the Ai2 lease was announced in July 2024. The Allen Institute for AI (Ai2) is separate from the AI2 Incubator, which spun off from the non-profit and has its own new waterfront home, AI House, at Pier 70 on Elliott Bay. Keep scrolling for more pictures from inside the new Ai2 space. The view across the open-air courtyard at Northlake Commons, the mass-timber building that now houses Ai2's new headquarters. (GeekWire Photos / Todd Bishop) A grouping of workstations inside the new Ai2 headquarters. The entrance to a new podcast and video studio at the Ai2 headquarters. A large common area overlooking Lake Union. The Ai2 logo inside the common room of the new headquarters. RELATED STORY: Allen Institute for AI lands $152M from Nvidia and NSF to lead national AI project

SpaceX delays Starlink mission from California again. Will it be visible in Arizona?
SpaceX delays Starlink mission from California again. Will it be visible in Arizona?

Yahoo

time6 days ago

  • Yahoo

SpaceX delays Starlink mission from California again. Will it be visible in Arizona?

Nearly midway through August, SpaceX has yet to launch its first rocket from Southern California. But that doesn't mean the commercial spaceflight company founded by billionaire Elon Musk hasn't tried. SpaceX has been attempting to launch its Falcon 9 rocket since Aug. 9 on a mission to deploy internet-beaming Starlink satellites from the Vandenberg Space Force Base in Santa Barbara County. That mission has so far been postponed three times, which appears to have caused a ripple effect for the remainder of the missions scheduled for August at the company's launch pad at the California base. For neighboring Arizonans hoping to glimpse the site of the spacecraft soaring overhead, the moving schedule may have caused some confusion. Here's everything to know about where things stand with SpaceX rocket launches at Vandenberg. When is the next rocket launch from the Vandenberg Space Force Base in California? SpaceX is now working toward a Wednesday, Aug. 13, liftoff of its Falcon 9 rocket from the Vandenberg Space Force Base, with a four-hour launch window opening at 8:44 p.m. PT, the base said in a launch alert. The two-stage 230-foot Falcon 9 rocket, one of the world's most active, is scheduled to deliver 24 Starlink satellites into low-Earth orbit – an altitude low enough to allow for things like satellites to circle Earth fairly quickly. As with most SpaceX missions, the launch will be available to stream on the company's website beginning about five minutes before liftoff. SpaceX may also provide updates on social media site X. 1st SpaceX Starlink launch of August delayed 3 times in California: What we know The mission, known as Starlink 17-4, has been postponed three times since its original target date of Aug. 9. Vandenberg and SpaceX had also been planning for the mission to get off the ground Aug. 11, then Aug. 12 before both attempts were scrubbed. No reasons have been provided for the delays. A spokeswoman for Vandenberg deferred questions to SpaceX when reached Wednesday, Aug. 13, by the USA TODAY Network. What other missions are scheduled for August so far? SpaceX had also been planning another Starlink deployment mission, 17-5 in the same week of August. The company has not yet updated the mission's target launch date online, but multiple websites that track rocket launches suggest it's scheduled for Friday, Aug. 15. The launch window could possibly open at 8:44 a.m. PT. Vandenberg has not yet officially announced the launch, which is also not listed on a Federal Aviation Administration operations plan advisory. Here's a look at other missions planned for the month: Tuesday, Aug. 19: Starlink 17-6 Thursday, Aug. 21: Starlink 17-7 Sunday, Aug. 24: Bandwagon 4 Where to watch rocket launches in Arizona Because of Arizona's proximity to the launch site, there's a good chance people there can see the spacecraft streak across the sky, especially at night or very early morning. Here's a list of some possible viewing locations compiled by The Arizona Republic, a USA TODAY Network publication. Dobbins Lookout, South Mountain, 10919 S. Central Ave., Phoenix, Arizona Papago Park, 625 N. Galvin Parkway, Phoenix, Arizona Fountain Hills, a town in Maricopa County, Arizona, which in 2018 was designated a Dark Sky Community with little light pollution Superstition Mountains, located 40 miles from metro Phoenix in Arizona Cave Creek, a town in Maricopa County about 30 miles north of Fountain Hills, Arizona Phoenix Sky Harbor International Airport, 3400 Sky Harbor Blvd., Arizona, which has a parking garage that is popular for plane-watching Black Canyon City, an unincorporated community in Yavapai County, Arizona Any mountain park in Arizona , 14805 W. Vineyard Ave., Goodyear, Arizona , 2600 N. Watson Road, Buckeye, Arizona , 20304 W. White Tank Mountain Road, Waddell, Arizona , 6533 W. Phillips Road, Queen Creek, Arizona Monument Hill, a 150-foot slope on 115th Avenue, in Arizona Casa Grande, a city in Pinal County, approximately halfway between Phoenix and Tucson Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@ This article originally appeared on Arizona Republic: SpaceX rocket launch delayed again in California. Will Arizona see it? Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store